Key result
This review summarizes the development of anthracyclines, addressing the impact of structural modifications on antitumour activity, cardiotoxicity, and multidrug resistance.
Why the study?
Multidrug resistance and severe cardiotoxicity are major limitations of anthracycline chemotherapy that have prompted the development of novel analogues.
This review summarizes the development of anthracyclines, highlighting their antitumour efficacy and the ongoing efforts to mitigate limitations such as multidrug resistance and severe cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Highlights structural strategies to mitigate anthracycline cardiotoxicity; leaves open need for randomized trials confirming clinical benefit.
Martins-Teixeira et al. (2020) conducted a review in Cancer. Anthracyclines was evaluated. This review summarizes the development of anthracyclines, addressing the impact of structural modifications on antitumour activity, cardiotoxicity, and multidrug resistance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: